Last reviewed 2026-04-20 · How we verify

Lerochol (LERODALCIBEP)

Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels.

At a glance

Mechanism of action

Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. [see Clinical Pharmacology ( 12.3 )] .

Approved indications

• hypercholesterolemia
• heterozygous familial hypercholesterolemia (HeFH)

Common side effects

• Nasopharyngitis
• Injection site reactions
• Peripheral edema
• Diarrhea
• Nausea

Key clinical trials

• Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH (PHASE3)
• A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants (PHASE1)
• A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia (PHASE3)
• Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (PHASE3)
• Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (PHASE3)
• Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (PHASE3)
• Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (PHASE3)
• Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.